FRESENIUS SE & CO KGAA (1FRE.MI) Stock Price & Overview

BIT:1FREDE0005785604

Current stock price

47.28 EUR
-2.53 (-5.08%)
Last:

The current stock price of 1FRE.MI is 47.28 EUR. Today 1FRE.MI is down by -5.08%. In the past month the price increased by 77.31%.

1FRE.MI Key Statistics

1-Month Range25 - 50.12
Current 1FRE.MI stock price positioned within its 1-month range.
Market Cap
26.63B
P/E
13.87
Fwd P/E
12.36
EPS (TTM)
3.41
Dividend Yield
1.92%

1FRE.MI Stock Performance

Today
-5.08%
1 Week
+5.62%
1 Month
+77.31%
3 Months
N/A
Longer-term
6 Months N/A
1 Year N/A
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A

1FRE.MI Stock Chart

FRESENIUS SE & CO KGAA / 1FRE Daily stock chart

1FRE.MI Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to 1FRE.MI.


Chartmill TA Rating
Chartmill Setup Rating

1FRE.MI Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to 1FRE.MI. Both the profitability and the financial health of 1FRE.MI get a neutral evaluation. Nothing too spectacular is happening here.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

1FRE.MI Earnings

On November 5, 2025 1FRE.MI reported an EPS of 0.83 and a revenue of 5.49B. The company beat EPS expectations (13.53% surprise) and missed revenue expectations (-4.68% surprise).

Next Earnings DateFeb 25, 2026
Last Earnings DateNov 5, 2025
PeriodQ3 / 2025
EPS Reported€0.83
Revenue Reported5.485B
EPS Surprise 13.53%
Revenue Surprise -4.68%

1FRE.MI Forecast & Estimates

23 analysts have analysed 1FRE.MI and the average price target is 56.15 EUR. This implies a price increase of 18.77% is expected in the next year compared to the current price of 47.28.

For the next year, analysts expect an EPS growth of 13.8% and a revenue growth 4.32% for 1FRE.MI


Analysts
Analysts85.22
Price Target56.15 (18.76%)
EPS Next Y13.8%
Revenue Next Year4.32%

1FRE.MI Groups

Sector & Classification

Index Membership

1FRE.MI Financial Highlights

Over the last trailing twelve months 1FRE.MI reported a non-GAAP Earnings per Share(EPS) of 3.41. The EPS increased by 215.74% compared to the year before.


Income Statements
Revenue(TTM)22.35B
Net Income(TTM)1.14B
Industry RankSector Rank
PM (TTM) 5.11%
ROA 2.69%
ROE 6.14%
Debt/Equity 0.61
Chartmill High Growth Momentum
EPS Q2Q%20.29%
Sales Q2Q%2.22%
EPS 1Y (TTM)215.74%
Revenue 1Y (TTM)2.13%

1FRE.MI Ownership

Ownership
Inst Owners46.56%
Shares563.24M
Float411.13M
Ins OwnersN/A
Short Float %N/A
Short RatioN/A

About 1FRE.MI

Company Profile

1FRE logo image Fresenius SE & Co. KGaA is a healthcare group, which engages in the provision of products and services for dialysis, hospitals, and outpatient medical care. The company is headquartered in Bad Homburg, Hessen and currently employs 177,356 full-time employees. The firm has operationally managed divisions Fresenius Kabi and Fresenius Helios as well as the holdings Fresenius Vamed and Fresenius Medical Care. Fresenius Kabi offers healthcare products for critically and chronically ill patients and offers essential medicines and medical technology for infusion, transfusion and clinical nutrition and its product portfolio includes intravenously administered generic medicines, infusion therapies and clinical nutrition. Fresenius Helios is a private hospital operator that operates clinics, medical facilities, rehabilitation centers and others. Fresenius Vamed provides services for hospitals and other healthcare facilities such as prevention, construction, service and operational management. Fresenius Medical Care offers products and services along the dialysis value chain and is a supplier of dialysis products such as dialysis machines, dialyzers and associated disposable accessories.

Company Info

IPO: 1986-12-18

FRESENIUS SE & CO KGAA

Else-Kroener-Str. 1

BAD HOMBURG HESSEN DE

Employees: 177356

1FRE Company Website

1FRE Investor Relations

Phone: 4961726080

FRESENIUS SE & CO KGAA / 1FRE.MI FAQ

What does FRESENIUS SE & CO KGAA do?

Fresenius SE & Co. KGaA is a healthcare group, which engages in the provision of products and services for dialysis, hospitals, and outpatient medical care. The company is headquartered in Bad Homburg, Hessen and currently employs 177,356 full-time employees. The firm has operationally managed divisions Fresenius Kabi and Fresenius Helios as well as the holdings Fresenius Vamed and Fresenius Medical Care. Fresenius Kabi offers healthcare products for critically and chronically ill patients and offers essential medicines and medical technology for infusion, transfusion and clinical nutrition and its product portfolio includes intravenously administered generic medicines, infusion therapies and clinical nutrition. Fresenius Helios is a private hospital operator that operates clinics, medical facilities, rehabilitation centers and others. Fresenius Vamed provides services for hospitals and other healthcare facilities such as prevention, construction, service and operational management. Fresenius Medical Care offers products and services along the dialysis value chain and is a supplier of dialysis products such as dialysis machines, dialyzers and associated disposable accessories.


Can you provide the latest stock price for FRESENIUS SE & CO KGAA?

The current stock price of 1FRE.MI is 47.28 EUR. The price decreased by -5.08% in the last trading session.


Does FRESENIUS SE & CO KGAA pay dividends?

FRESENIUS SE & CO KGAA (1FRE.MI) has a dividend yield of 1.92%. The yearly dividend amount is currently 0.


What is the ChartMill technical and fundamental rating of 1FRE stock?

1FRE.MI has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 4 out of 10.


On which exchange is 1FRE.MI stock listed?

1FRE.MI stock is listed on the Euronext Milan exchange.


Is FRESENIUS SE & CO KGAA (1FRE.MI) stock a good buy?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on 1FRE.MI.


Can you provide the growth outlook for FRESENIUS SE & CO KGAA?

The Revenue of FRESENIUS SE & CO KGAA (1FRE.MI) is expected to grow by 4.32% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.